Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Name: Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
SKU: 22176
Price: 30.00 USD
Availability: InStock

$30.00

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Category: VOL 48 No. 4 Articles – 2018 Tags: antidepressant agents, antipsychotic-agents, cariprazine, clinical-trial, depressive-disorder, major-depressive-disorder, Phase 3, randomized-placebo-controlled-trial, treatment-resistant, Vraylar

Description

Description

Original Research

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

By Willie R. Earley, Hua Guo, György Németh, Judit Harsányi, Michael E. Thase

62-80_PB-48-4-2018-Earley

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Description

Original Research

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Psychopharmacology Bulletin VOL 48 No. 4, 2018 – Full Issue Stacked PDF

Trazodone for Depressed Mood, Anxiety, Insomnia, and Suicidality

Paroxetine Treatment of Major Depressive Disorder

Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial

Description

Original Research

Related products

Asenapine in the Treatment of Negative Symptoms of Schizophrenia: Clinical Trial Design and Rationale

Psychopharmacology Bulletin VOL 48 No. 4, 2018 – Full Issue Stacked PDF

Trazodone for Depressed Mood, Anxiety, Insomnia, and Suicidality

Paroxetine Treatment of Major Depressive Disorder